ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013

  ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012
  Financial Results on March 12, 2013

ACADIA to Host Conference Call and Webcast on Tuesday, March 12, 2013, at 5:00
                              p.m. Eastern Time

Business Wire

SAN DIEGO -- March 5, 2013

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today announced
that it will report its financial results for the fourth quarter and year
ended December 31, 2012 on Tuesday, March 12, 2013, after the U.S. financial
markets close. ACADIA's management will host a conference call and webcast on
Tuesday, March 12, 2013, at 5:00 p.m. Eastern Time to discuss ACADIA’s
financial results and development programs.

The conference call may be accessed by dialing 866-510-0712 for participants
in the U.S. or Canada and 617-597-5380 for international callers (reference
passcode 78191729). A telephone replay of the conference call may be accessed
through March 26, 2013 by dialing 888-286-8010 for callers in the U.S. or
Canada and 617-801-6888 for international callers (reference passcode
59394169). The conference call also will be webcast live on ACADIA’s website,
www.acadia-pharm.com, under the investors section and will be archived there
until March 26, 2013.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two
advanced preclinical programs directed at Parkinson’s disease and other
neurological disorders. All product candidates are small molecules that
emanate from discoveries made at ACADIA. ACADIA maintains a website at
www.acadia-pharm.com to which ACADIA regularly posts copies of its press
releases as well as additional information and through which interested
parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements include but are not limited
to statements related to the progress and timing of ACADIA’s drug discovery
and development programs, either alone or with a partner, including clinical
trials, and the benefits to be derived from ACADIA’s product candidates, in
each case including pimavanserin. These statements are only predictions based
on current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including the
risks and uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that past
results of clinical trials may not be indicative of future trial results. For
a discussion of these and other factors, please refer to ACADIA’s annual
report on Form 10-K for the year ended December31, 2011 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this cautionary
statement and ACADIA undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof, except as
required by law.

Contact:

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
858-558-2871
 
Press spacebar to pause and continue. Press esc to stop.